Pascal Soriot

Strong demand for AstraZeneca’s new drugs – especially those for cancer – drove a return to sales growth in the third quarter and the drugmaker said i(...)

Shares in AstraZeneca were on track to suffer their worst ever fall after the Anglo-Swedish pharmaceutical company suffered a big setback with a much-(...)

In a week when the UK’s Eurosceptic international trade minister Liam Fox suggested the British economy could easily manage without a trade deal with (...)

Emma Walmsley, poised to take over as the first female chief executive of GlaxoSmithKline, will earn about a quarter less than her predecessor Andrew (...)

Pharmaceutical giant AstraZeneca expects major US healthcare changes after Donald Trump’s election victory but its chief executive warned on Thursday (...)

GlaxoSmithKline plans £275 million of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite (...)

AstraZeneca warned on Thursday that revenue and earnings would drop this year due to the arrival of cheap generic rivals to Crestor, its top-selling c(...)

AstraZeneca agreed to buy a 55 per cent stake in Acerta Pharma for $4 billion to gain a potential blockbuster cancer medicine. The UK’s second-large(...)

Britain’s AstraZeneca has agreed to buy US biotech company ZS Pharma for $2.7 billion, pipping Swiss firm Actelion to the prize in the latest bout of (...)

AstraZeneca, the second-largest UK drug maker, said fourth-quarter earnings fell 33 per cent as revenue declined for two of its best-selling drugs and(...)